window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

kidney transplantation

  • Biologics & Biosimilars,Biomanufacturing,Biotech,Clinical Development,Clinical Trials,Drug approval,Drug Development,FDA,Rare Diseases,Research & Development

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    February 19, 2026
  • Biologics & Biosimilars,Clinical Development,Drug approval,FDA,Funding,Pharmaceuticals and therapeutics,Rare Diseases,Regulatory Affairs

    Hansa Biopharma reports 135% Q4 revenue growth and BLA submission for imlifidase

    Hansa Biopharma has reported a 135% increase in fourth-quarter revenue [...]

    February 13, 2026
  • Biologics & Biosimilars,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Global health,Medical devices,Pharmaceuticals and therapeutics,Regulatory Affairs

    Hansa Biopharma reports statistically significant improvement in kidney function, supporting planned BLA submission

    Hansa Biopharma AB has announced positive topline results from the [...]

    September 26, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical Development, Clinical studies, Hematology, Regulatory Affairs, Research & Development
  • Symbiosis expands QC capabilities with new 30°C stability chamber
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Manufacturing, Pharmaceuticals and therapeutics
  • Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed
    Categories: Clinical Trials, Immunology, Oncology, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top